CHC

Limousin W, Laurent-Puig P, Ziol M, Ganne-Carrié N, Nahon P, Ait-Omar A, Seror O, Sidali S, Campani C, Blanc P, Lermine A, Marisa L, Zucman-Rossi J, Nault JC.J Hepatol. 2023 Dec;79(6):1450-1458. doi: 10.1016/j.jhep.2023.08.017. Epub 2023 Aug 28.PMID: 37647991 Background & aims: The “French Medicine Genomic program 2025” has been designed to give patients with cancers …

Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab Read More »

Nahon P, Bamba-Funck J, Layese R, Trépo E, Zucman-Rossi J, Cagnot C, Ganne-Carrié N, Chaffaut C, Guyot E, Ziol M, Sutton A, Audureau E; ANRS CO12 CirVir and CIRRAL groups. J Hepatol. 2023 Mar;78(3):584-595. doi: 10.1016/j.jhep.2022.11.003. Background & aims: Identifying individuals at higher risk of developing hepatocellular carcinoma (HCC) is pivotal to improve the performance …

Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis Read More »

Campani C, Bamba-Funck J, Campion B, Sidali S, Blaise L, Ganne-Carrié N, Demory A, Sutter O, Larrey E, Evain M, Ghannouchi H, Wagner M, Marra F, Sutton A, Allaire M, Nault JC. Liver Int. 2023 Mar;43(3):708-717. doi: 10.1111/liv.15487. Epub 2022 Dec 14. Background: The combination of atezolizumab and bevacizumab (AtezoBev) is the current first-line treatment …

Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab Read More »

Sidali S, Sritharan N, Campani C, Gregory J, Durand F, Ganne-Carrié N, Ronot M, Lévy V, Nault JC. JHEP Rep. 2023 Apr 7;5(7):100755. doi: 10.1016/j.jhepr.2023.100755. Background & aims: The fragility index (FI), i.e., theminimum number of best survivors reassigned to the control group required to revert the statistically significant result of a clinical trial to …

Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002-2022) Read More »

Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, Yang JD, Reig M, Cabibbo G, Nahon P, Parikh ND, Marrero JA. Abstract Background & aims: There is controversy regarding the overall value of hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis given the lack of data from randomized-controlled trials. To address this issue, we …

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis Read More »

Nahon P, Ronot M. Lire l’article

Ramtohul T, Vilgrain V, Soubrane O, Bouattour M, Luciani A, Kobeiter H, Mule S, Tacher V, Laurent A, Amaddeo G, Regnault H, Bulsei J, Nault JC, Nahon P, Durand-Zaleski I, Seror O. Abstract Background: To evaluate the cost-effectiveness of the extended use of ablation for the treatment of hepatocellular carcinoma (HCC) with cirrhosis in an expert ablation …

Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis Read More »

Muñoz-Martínez S, Sapena V, Forner A, Bruix J, Sanduzzi-Zamparelli M, Ríos J, Bouattour M, El-Kassas M, Leal CRG, Mocan T, Nault JC, Alves RCP, Reeves HL, da Fonseca L, García-Juárez I, Pinato DJ, Varela M, Alqahtani SA, Alvares-da-Silva MR, Bandi JC, Rimassa L, Lozano M, González Santiago JM, Tacke F, Sala M, Anders M, Lachenmayer A, …

Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study Read More »